-
公开(公告)号：US20240316066A1
公开(公告)日：2024-09-26
申请号：US18676998
申请日：2024-05-29
Applicant: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Darren WILLIAMS , Hyunju LEE , Da-Woon JUNG , Eun-Mi JANG , Jihee SOH
IPC: A61K31/58 , A61K31/192 , A61K31/47 , A61K31/506 , A61K31/5375 , A61K45/06 , A61P35/00 , C12Q1/6886 , G01N33/50
CPC classification number: A61K31/58 , A61K31/192 , A61K31/47 , A61K31/506 , A61K31/5375 , A61K45/06 , A61P35/00 , C12Q1/6886 , G01N33/5011 , G01N33/5023 , G01N2333/91215
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising a PIP4K2C inhibitor as an active ingredient. The present invention provides a composition for efficient and radical treatment of cancer by discovering PIP4K2C as a new treatment target for cancer, which exhibits a high recurrence rate and is difficult to radically treat, and selecting a drug that inhibits PIP4K2C among known anticancer drugs.
-
公开(公告)号：US20240151723A1
公开(公告)日：2024-05-09
申请号：US18549001
申请日：2022-03-03
Applicant: Neolys Diagnostics , Alara Group
Inventor： Sandrine Pereira , Fanny Carbillet
IPC: G01N33/573
CPC classification number: G01N33/573 , G01N2333/91215 , G01N2440/14 , G01N2800/52
Abstract: A method for estimating a toxicity level of radiation therapy on a patient comprises characterizing radiosensitivity of a cell sample from the patient to ionizing radiation to determine a first radiosensitivity factor by biochemical analysis. The first radiosensitivity factor is determined by biochemical analysis of a sample collected from the patient under examination in a basal state, to quantify a marker or a combination of markers. Dosimetric data is analyzed using data originating from treatment planning to determine a second treatment factor. The level of toxicity is determined by a combination of the first radiosensitivity factor and the second treatment factor. The method may be used to assess the risk factors of a radiation therapy treatment on a patient suffering from, for example, cancer to determine whether the patient will be able to tolerate further radiation without there being a major, or even lethal, toxicological risk.
-
公开(公告)号：US10004748B2
公开(公告)日：2018-06-26
申请号：US14717069
申请日：2015-05-20
Applicant: Genentech, Inc.
Inventor： Mika K. Derynck , Lori Friedman , Steven Brian Gendreau , Sandra Milan
IPC: A61K31/5377 , A61K45/06 , C12Q1/68 , A61K31/4196 , A61K31/565 , C12Q1/6886 , G01N33/574 , G01N33/50 , A61K31/381 , A61K31/495
CPC classification number: A61K31/5377 , A61K31/381 , A61K31/4196 , A61K31/495 , A61K31/565 , A61K45/06 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , G01N33/5011 , G01N33/57415 , G01N2333/91215 , G01N2333/916
Abstract: Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
-
4.发明申请
公开(公告)号：US20180112250A1
公开(公告)日：2018-04-26
申请号：US15788076
申请日：2017-10-19
Applicant: ARKRAY, Inc.
Inventor： Takehiro Funamoto , Masaki Murakami
CPC classification number: C12Q1/32 , C12Q1/25 , C12Q1/485 , C12Q1/54 , C12Y101/01049 , C12Y603/01002 , G01N2333/904 , G01N2333/91215
Abstract: A method of quantifying ammonia, which method includes: performing a first reaction in which a test liquid containing ammonia is reacted with ATP and L-glutamic acid in the presence of glutamine synthetase to produce ADP; performing a second reaction in which the produced ADP is reacted with glucose in the presence of ADP-dependent hexokinase to produce glucose-6-phosphate; performing a third reaction in which the produced glucose-6-phosphate is reacted with an oxidized NAD compound in the presence of glucose-6-phosphate dehydrogenase to produce a reduced NAD compound; and quantifying the reduced NAD compound to quantify ammonia.
-
公开(公告)号：US20180045741A1
公开(公告)日：2018-02-15
申请号：US15725712
申请日：2017-10-05
Inventor： Noriyuki Matsuda , Fumika Koyano , Kei Okatsu , Etsu Go , Mayumi Kimura , Yasushi Saeki
CPC classification number: G01N33/6896 , A61K38/00 , C07K14/47 , C07K16/18 , C12Q1/485 , C12Y207/11001 , G01N33/5079 , G01N2333/47 , G01N2333/912 , G01N2333/91215 , G01N2440/14 , G01N2500/00 , G01N2500/20 , G01N2800/2835
Abstract: An antibody has as a target molecule a ubiquitin protein comprising a phosphorylated serine residue at position 65. In addition, a method is provided for specifically detecting Parkinson's disease at an early stage, in which a target molecule is a ubiquitin protein comprising a phosphorylated serine residue at position 65, a pharmaceutical composition for definitively treating or preventing Parkinson's disease, and a method for screening for the pharmaceutical composition.
-
公开(公告)号：US09771430B2
公开(公告)日：2017-09-26
申请号：US14197173
申请日：2014-03-04
Inventor： Ira Tabas , Lale Ozcan
IPC: A61K31/00 , C12N9/99 , C07K16/40 , A01K67/027 , C07K14/705 , C12N9/12 , A61K31/47 , A61K31/472 , C12N15/113 , G01N33/50
CPC classification number: C07K16/40 , A01K67/0275 , A01K2207/05 , A01K2207/25 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/0362 , A61K31/47 , A61K31/472 , C07K14/705 , C12N9/1205 , C12N15/1137 , G01N33/5023 , G01N2333/91215 , G01N2500/10 , G01N2800/04
Abstract: The present invention relates to methods of treating or preventing a metabolic disorder in a subject, methods of treating or preventing coronary artery disease in a subject with a metabolic disorder, as well as methods of reducing hepatic glucose production in a subject. Such methods include, but are not limited to, the administration to the subject of inhibitors or activators of CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1, Dach2, or any combination thereof. The invention also provides methods of identifying a compound that inhibits the activity of CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1 or Dach2, or reduces the activity and/or activation of CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1 or Dach, or activates CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1 or Dach2.
-
公开(公告)号：US09568483B2
公开(公告)日：2017-02-14
申请号：US14112358
申请日：2012-03-28
Applicant: Mark A. Rubin , Himisha Beltran
Inventor： Mark A. Rubin , Himisha Beltran
IPC: C12Q1/68 , C07H21/04 , G01N33/68 , G01N33/574 , A61K31/00 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/675 , A61K31/713
CPC classification number: G01N33/6893 , A61K31/00 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/675 , A61K31/713 , C12Q1/6886 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , G01N33/57434 , G01N2333/82 , G01N2333/91215
Abstract: Disclosed herein are new prognostic molecular markers for prostate cancer. More specifically, the invention has identified that overexpression or amplification of at least one of AURKA or MYCN define a distinct subgroup of prostate cancer that is predisposed to the development of lethal NEPC, who will benefit from early intervention.
Abstract translation: 本文公开了用于前列腺癌的新的预后分子标记。 更具体地，本发明已经确定，AURKA或MYCN中的至少一种的过度表达或扩增定义了易于发生致死性NEPC的前列腺癌的不同亚组，其将受益于早期干预。
-
8.发明申请NATURAL-KILLER/T-CELL LYMPHOMA (NKTCL) SUSCEPTIBILITY PREDICTION, DIAGNOSIS AND THERAPY 审中-公开自然杀伤/ T细胞淋巴瘤（NKTCL）可疑预测，诊断和治疗
公开(公告)号：US20170029899A1
公开(公告)日：2017-02-02
申请号：US15174578
申请日：2016-06-06
Applicant: SINGAPORE HEALTH SERVICES PTE LTD
Inventor： Bin Tean Teh , Soon Thye Lim
IPC: C12Q1/68 , A01K67/027 , G01N33/574 , G01N33/50 , A61K31/519 , A61K31/277
CPC classification number: C12Q1/6886 , A01K67/0275 , A01K2267/0331 , A61K31/165 , A61K31/277 , A61K31/519 , C12Q2600/156 , C12Q2600/158 , G01N33/5011 , G01N33/57407 , G01N33/57426 , G01N2333/912 , G01N2333/91215 , G01N2800/50
Abstract: Natural-KilleifT-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.
Abstract translation: 天然KilleifT细胞淋巴瘤（NKTCL）敏感性预测，诊断和治疗。 本发明涉及一种用于预测自然杀伤T细胞淋巴瘤（NKTCL）易感性和/或诊断受试者中NKTCL的方法，包括测试JAK突变。 本发明还涉及使用包含至少一种JAK突变的细胞系筛选能够治疗NKTCL的候选药剂的方法。 本发明包括包含至少一种JAK突变的NKTCL动物模型。 本发明还包括用于治疗NKTCL的JAK抑制剂。
-
9.发明授权Compositions and methods for inducing myoblast differentiation and myotube formation 有权诱导成肌细胞分化和肌管形成的组合物和方法
公开(公告)号：US09506033B2
公开(公告)日：2016-11-29
申请号：US14401612
申请日：2013-05-21
Applicant: University of Massachusetts
Inventor： Michael P. Czech , Mengxi Wang
IPC: A61K48/00 , C12N5/077 , A61K45/06 , A61K31/7105 , A61K31/7115 , A61K31/712 , A61K31/7125 , A61K31/713 , G01N33/50 , C12N15/113 , A61K9/00 , A61K9/127 , A61K9/51
CPC classification number: C12N5/0658 , A61K9/0019 , A61K9/127 , A61K9/51 , A61K31/7105 , A61K31/7115 , A61K31/712 , A61K31/7125 , A61K31/713 , A61K45/06 , C12N15/1137 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2501/40 , C12N2506/1323 , C12Y207/11001 , G01N33/5023 , G01N33/5061 , G01N33/5073 , G01N2333/91205 , G01N2333/91215 , G01N2800/10
Abstract: Provided herein are methods of inducing differentiation of a mammalian myoblast into a mammalian myocyte that include contacting a mammalian myoblast with an oligonucleotide that decreases Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) mRNA expression in a mammalian myoblast or myocyte. Also provided are methods of inducing mammalian myoblasts or myocytes to form a myotube that include contacting two or more mammalian myoblasts or two or more mammalian myocytes with an oligonucleotide that decreases Map4k4 mRNA expression in a mammalian myoblast or myocyte. Also provided are methods of identifying a candidate agent useful for inducing muscle formation, and compositions containing an oligonucleotide that decreases Map4k4 mRNA expression in mammalian myoblast or myocyte and one or more additional muscle therapeutic agents and/or muscle-building neutraceuticals.
Abstract translation: 本文提供诱导哺乳动物成肌细胞分化为哺乳动物肌细胞的方法，其包括使哺乳动物成肌细胞与哺乳动物成肌细胞或肌细胞中降低丝裂原活化蛋白激酶激酶激酶4（Map4k4）mRNA表达的寡核苷酸接触。 还提供了诱导哺乳动物成肌细胞或肌细胞形成肌管的方法，其包括使两种或更多种哺乳动物成肌细胞或两种或更多种哺乳动物肌细胞与哺乳动物成肌细胞或肌细胞中降低Map4k4 mRNA表达的寡核苷酸接触。 还提供了鉴定用于诱导肌肉形成的候选药剂的方法，以及含有降低哺乳动物成肌细胞或肌细胞中的Map4k4mRNA表达的寡核苷酸和一种或多种另外的肌肉治疗剂和/或肌肉建立中性药物的组合物。
-
公开(公告)号：US20160251446A1
公开(公告)日：2016-09-01
申请号：US14909038
申请日：2014-07-30
Applicant: BLUEPRINT MEDICINES CORPORATION
Inventor： Nicolas STRANSKY , Ethan G. CERAMI , Joseph L. KIM , Christoph LENGAUER
IPC: C07K16/40 , A61K31/517 , G01N33/574 , C12N15/113 , C12Q1/68
CPC classification number: C07K16/40 , A61K31/517 , C07K2317/33 , C07K2317/34 , C12N15/1137 , C12N2310/14 , C12Q1/485 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158 , G01N33/57492 , G01N2333/91215 , G01N2800/7028
Abstract: The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins. The invention further provides methods of diagnosing and treating diseases or disorders associated with PK3C2G fusions, such as conditions mediated by aberrant PIK3C2G expression or activity, or conditions associated with overexpression of PIK.3C2G.
Abstract translation: 本发明提供了PIK3C2G（磷脂酰肌醇-4-磷酸-3-激酶，催化亚基2型γ）基因融合体和PIK3C2G融合蛋白。 本发明还提供诊断和治疗与PK3C2G融合相关的疾病或病症的方法，例如由异常PIK3C2G表达或活性介导的病症，或与PIK.3C2G的过度表达相关的病症。
